Kelun’s $250M PIPE; Valneva moves chikungunya vaccine to Phase 3 for kids
Title: Kelun Biotech Upsizes PIPE to $250M; Valneva Advances Chikungunya Vaccine to Phase 3 Trial Publication Date: June 6, 2025 As reported by Endpoints News on June 6, 2025, Sichuan-based company, Kelun Biotech, expanded its Private Investment in Public Equity…